Diversa, Glaxo Wellcome Pen Deal to Jointly Research Molecules | GenomeWeb

NEW YORK, Dec 12 - Diversa said Tuesday it had reached an agreement with Glaxo Wellcome to jointly research novel small molecules in Diversa’s PathwayLibraries.

Under the terms of the non-exclusive deal, Diversa and Glaxo Research and Development, a subsidiary of Glaxo Wellcome, will identify and screen molecules in the database for specific pharmaceutical activity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.